ASX:TLX Telix Pharmaceuticals (TLX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Telix Pharmaceuticals Stock (ASX:TLX) 30 days 90 days 365 days Advanced Chart Get Telix Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume746,789 shsAverage VolumeN/AMarket Capitalization$9.14 billionP/E Ratio290.42Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTelix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.Read More… Receive TLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TLX Stock News HeadlinesTelix Pharmaceuticals Limited: Telix's Illuccix PSMA-PET Imaging Agent Approved in the Czech RepublicMay 5, 2025 | finanznachrichten.deTelix Pharmaceuticals Limited: Telix's Illuccix PSMA-PET Imaging Agent Approved in FranceApril 29, 2025 | finanznachrichten.deTrump’s Secret WeaponWall Street is nervous. Billionaires are shifting assets. And everyday investors? Most are completely unprepared. Now that Trump is officially back in the White House, his aggressive new tariffs are already making waves—and this could be the beginning of a historic market crash. Elon Musk warns it's "foolish to bet against volatility right now." And with Trump pushing for the biggest trade war in history, the markets are bracing for impact.May 10, 2025 | American Alternative (Ad)Telix setback in drug approval in US, amid Trump workforce cuts to FDAApril 28, 2025 | afr.comTelix Pharmaceuticals Ltd ADR (TLX)April 27, 2025 | investing.comTelix: A masterclass in what this game is all aboutApril 24, 2025 | msn.comHealth Check: Telix shares rocket after bullish quarterly sales updateApril 23, 2025 | msn.comThe ASX's hottest company has gone from zero revenue to $1.2 billion in 4 yearsApril 23, 2025 | msn.comSee More Headlines TLX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Telix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Telix Pharmaceuticals investors own include bluebird bio (BLUE), Atara Biotherapeutics (ATRA), Esperion Therapeutics (ESPR), Forte Biosciences (FBRX), Faraday Future Intelligent Electric (FFIE), Abbott Laboratories (ABT) and ADMA Biologics (ADMA). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:TLX CIKN/A Webwww.telixpharma.com Phone61 4 4914 8448FaxN/AEmployees234Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.15 Trailing P/E Ratio290.42 Forward P/E RatioN/A P/E GrowthN/ANet Income$49.19 million Net Margins6.63% Pretax MarginN/A Return on Equity11.29% Return on Assets7.97% Debt Debt-to-Equity Ratio5.48 Current Ratio0.99 Quick Ratio3.00 Sales & Book Value Annual Sales$645.68 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow8.35 Book ValueA$1.21 per share Price / BookN/AMiscellaneous Outstanding Shares334,680,000Free FloatN/AMarket Cap$9.14 billion OptionableNot Optionable Beta2.40 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (ASX:TLX) was last updated on 5/10/2025 by MarketBeat.com Staff From Our PartnersWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Remember when they said crypto would never go mainstream? Well, something remarkable has happened… Blac...Crypto 101 Media | SponsoredThis robot is coming to 65 million Americans … this year.The Robotics Revolution has arrived. And not surprisingly, Nvidia is leading the way. Nvidia CEO Jensen ...Weiss Ratings | SponsoredTrump’s Secret WeaponBrace yourself. Trump is back in office—and he's wasting no time. 60% tariffs. A new trade war with China....American Alternative | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredNew breed of trader (Wall Street hates us?)Wall Street big wigs and old-money bankers can’t touch this 1 type of stock. And that opens the door for tr...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.